DiaMedica Therapeutics Inc.(DMAC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DMAC Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for DiaMedica Therapeutics Inc. (DMAC), a Healthcare sector company. DMAC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), DiaMedica Therapeutics Inc. reports net income of $-10.1M, free cash flow of $-8.1M. Top institutional holders of DMAC by reported 13-F value include COOPERMAN LEON G, BlackRock, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. DMAC trades on the Nasdaq exchange and files with the SEC under CIK 1401040. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DMAC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DiaMedica Therapeutics Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-10.1M
Free Cash Flow
Q2 2026
$-8.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-34.0% YoYOperating Income
-28.9% YoYTotal Assets
+32.4% YoYOp. Cash Flow
-31.6% YoYFree Cash Flow
-31.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-32.8M -34.0% | $-24.4M -26.1% | $-19.4M -41.7% | $-13.7M -0.6% | $-13.6M -10.6% | $-12.3M |
| Operating Income | $-34.4M -28.9% | $-26.7M -25.5% | $-21.3M -51.9% | $-14.0M -2.6% | $-13.6M -7.5% | $-12.7M |
| Total Assets | $61.4M +32.4% | $46.3M -14.4% | $54.2M +57.5% | $34.4M -24.5% | $45.6M +62.1% | $28.1M |
| Operating Cash Flow | $-29.1M -31.6% | $-22.1M -17.9% | $-18.7M -62.7% | $-11.5M +6.0% | $-12.3M -33.4% | $-9.2M |
| Free Cash Flow | $-29.1M -31.7% | $-22.1M -17.9% | $-18.8M -61.8% | $-11.6M +5.6% | $-12.3M -33.0% | $-9.2M |
Get alerted when DMAC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for DiaMedica Therapeutics Inc. including:
Top Institutional Holders of DMAC
COOPERMAN LEON G
$24.3M3,450,000 shBlackRock, Inc.
$15.9M2,252,285 shGEODE CAPITAL MANAGEMENT, LLC
$6.3M894,115 shMILLENNIUM MANAGEMENT LLC
$6.0M845,309 shSTATE STREET CORP
$4.6M646,743 shBleichroeder LP
$2.7M382,317 shVANGUARD CAPITAL MANAGEMENT LLC
$2.5M355,523 shOSAIC HOLDINGS, INC.
$2.4M338,107 shNORTHERN TRUST CORP
$2.3M327,518 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.8M251,671 sh
| Fund | Value | Shares |
|---|---|---|
| COOPERMAN LEON G | $24.3M | 3,450,000 |
| BlackRock, Inc. | $15.9M | 2,252,285 |
| GEODE CAPITAL MANAGEMENT, LLC | $6.3M | 894,115 |
| MILLENNIUM MANAGEMENT LLC | $6.0M | 845,309 |
| STATE STREET CORP | $4.6M | 646,743 |
| Bleichroeder LP | $2.7M | 382,317 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.5M | 355,523 |
| OSAIC HOLDINGS, INC. | $2.4M | 338,107 |
| NORTHERN TRUST CORP | $2.3M | 327,518 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.8M | 251,671 |
More Healthcare Companies
View all Healthcare →Put DMAC on your watchlist
Track score changes the day DiaMedica Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DMAC a good stock to buy?
13F Pro's AI-powered analysis of DiaMedica Therapeutics Inc. (DMAC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DMAC are available on the DMAC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DMAC is classified as a small company.
Which hedge funds own DMAC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DMAC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DiaMedica Therapeutics Inc.'s investment landscape.